Why is Aclaris Therapeutics stock sliding today?

Aclaris Therapeutics (ACRS) shares fell after its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis failed to meet the primary endpoint and all secondary endpoints. Management said it will pursue external business development for bosakitug.

Original reporting
Published Nov 16, 2026, 4:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRSBearishHigh
01

Why it matters

The trial failure is a material clinical‑trial disclosure that directly caused the stock slide, making the news highly actionable for short positions.

02

Market read

The immediate price impact and the significance of the trial result make this a high‑value trading signal for the stock.

03

What to watch

Remaining pipeline programs (ATI‑052 and modzatinib) may offset the setback if they show positive data.

Relevance 8/10Novelty 9/10Timing: today

Background

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial in atopic dermatitis failed to meet primary and secondary endpoints, prompting an 8% intraday share decline.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Phase 2 trial failure of bosakitug caused an 8.2% mid‑day drop in Aclaris Therapeutics shares.

Expected impact

likely further downside as investors reassess the company's pipeline and seek cash for the failed asset.

Evidence & confidence

The article is the first report of the trial result, which triggered a sharp price move; no mitigating news offsets the impact.

Market effects

Negative pressure on the broader biotech sector as the failure highlights challenges in atopic dermatitis programs.

U.S. market impact, especially among Nasdaq‑listed biotech stocks.

Limited to investors tracking U.S. biotech pipelines; no immediate global macro effect.

Counterpoint

If the company successfully monetises bosakitug via a sale or partnership, the stock could rebound.

Key entities

  • Aclaris Therapeutics

    Biopharma developing antibody and kinase inhibitor programs.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.

$ACRSMed

Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.